These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 12505808)

  • 21. Intramuscular testosterone supplementation to selective serotonin reuptake inhibitor in treatment-resistant depressed men: randomized placebo-controlled clinical trial.
    Seidman SN; Miyazaki M; Roose SP
    J Clin Psychopharmacol; 2005 Dec; 25(6):584-8. PubMed ID: 16282843
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial.
    Brecht S; Desaiah D; Marechal ES; Santini AM; Podhorna J; Guelfi JD
    J Clin Psychiatry; 2011 Aug; 72(8):1086-94. PubMed ID: 20868642
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of aromatase inhibition on sexual function and well-being in postmenopausal women treated with testosterone: a randomized, placebo-controlled trial.
    Davis SR; Goldstat R; Papalia MA; Shah S; Kulkarni J; Donath S; Bell RJ
    Menopause; 2006; 13(1):37-45. PubMed ID: 16607097
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient-rated troubling symptoms of depression instrument results correlate with traditional clinician- and patient-rated measures: a secondary analysis of a randomized, double-blind, placebo-controlled trial.
    Pandina GJ; Revicki DA; Kleinman L; Turkoz I; Wu JH; Kujawa MJ; Mahmoud R; Gharabawi GM
    J Affect Disord; 2009 Nov; 118(1-3):139-46. PubMed ID: 19321206
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.
    Trivedi MH; Thase ME; Fava M; Nelson CJ; Yang H; Qi Y; Tran QV; Pikalov A; Carlson BX; Marcus RN; Berman RM
    J Clin Psychiatry; 2008 Dec; 69(12):1928-36. PubMed ID: 19192475
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of testosterone gel 1% augmentation in depressed men with partial response to antidepressant therapy.
    Orengo CA; Fullerton L; Kunik ME
    J Geriatr Psychiatry Neurol; 2005 Mar; 18(1):20-4. PubMed ID: 15681624
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low-Dose Testosterone Augmentation for Antidepressant-Resistant Major Depressive Disorder in Women: An 8-Week Randomized Placebo-Controlled Study.
    Dichtel LE; Carpenter LL; Nyer M; Mischoulon D; Kimball A; Deckersbach T; Dougherty DD; Schoenfeld DA; Fisher L; Cusin C; Dording C; Trinh NH; Pedrelli P; Yeung A; Farabaugh A; Papakostas GI; Chang T; Shapero BG; Chen J; Cassano P; Hahn EM; Rao EM; Brady RO; Singh RJ; Tyrka AR; Price LH; Fava M; Miller KK
    Am J Psychiatry; 2020 Oct; 177(10):965-973. PubMed ID: 32660299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
    Davidson JR; Meoni P; Haudiquet V; Cantillon M; Hackett D
    Depress Anxiety; 2002; 16(1):4-13. PubMed ID: 12203668
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The sexual effects of testosterone replacement in depressed men: randomized, placebo-controlled clinical trial.
    Seidman SN; Roose SP
    J Sex Marital Ther; 2006; 32(3):267-73. PubMed ID: 16809253
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An open-label, pilot study evaluating the safety and antidepressant effects of Rellidep in major depressive disorder.
    Sadavoy J; Bain J
    J Clin Psychopharmacol; 2014 Apr; 34(2):230-3. PubMed ID: 24304858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. One-year efficacy and safety study of a 1.62% testosterone gel in hypogonadal men: results of a 182-day open-label extension of a 6-month double-blind study.
    Kaufman JM; Miller MG; Fitzpatrick S; McWhirter C; Brennan JJ
    J Sex Med; 2012 Apr; 9(4):1149-61. PubMed ID: 22321357
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The beneficial effects of the herbal medicine Free and Easy Wanderer Plus (FEWP) for mood disorders: double-blind, placebo-controlled studies.
    Zhang ZJ; Kang WH; Li Q; Tan QR
    J Psychiatr Res; 2007 Nov; 41(10):828-36. PubMed ID: 17010995
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Curcumin as an add-on to antidepressive treatment: a randomized, double-blind, placebo-controlled, pilot clinical study.
    Bergman J; Miodownik C; Bersudsky Y; Sokolik S; Lerner PP; Kreinin A; Polakiewicz J; Lerner V
    Clin Neuropharmacol; 2013; 36(3):73-7. PubMed ID: 23673908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G; Beeské S; Stahl SM
    J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
    Reed CR; Kajdasz DK; Whalen H; Athanasiou MC; Gallipoli S; Thase ME
    Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.
    Arnold LM; Lu Y; Crofford LJ; Wohlreich M; Detke MJ; Iyengar S; Goldstein DJ
    Arthritis Rheum; 2004 Sep; 50(9):2974-84. PubMed ID: 15457467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
    Marcus RN; McQuade RD; Carson WH; Hennicken D; Fava M; Simon JS; Trivedi MH; Thase ME; Berman RM
    J Clin Psychopharmacol; 2008 Apr; 28(2):156-65. PubMed ID: 18344725
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression.
    Barbee JG; Thompson TR; Jamhour NJ; Stewart JW; Conrad EJ; Reimherr FW; Thompson PM; Shelton RC
    J Clin Psychiatry; 2011 Oct; 72(10):1405-12. PubMed ID: 21367355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Post hoc analysis of the efficacy and safety of desvenlafaxine 50 mg/day in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.
    Kornstein SG; Clayton A; Bao W; Guico-Pabia CJ
    Menopause; 2014 Aug; 21(8):799-806. PubMed ID: 24448103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.